Market news

Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Patrick Miles, Director, Chief Executive Officer, on September 10, 2026, executed a purchase for 115

Detailed price information for Alphatec Holdings (ATEC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Alphatec Holdings (ATEC-Q) from The Globe and Mail including charting and trades.

Alphatec Holdings Inc (ATEC) delivered 15% revenue growth and raised its full-year adjusted EBITDA outlook, while navigating a slower-than-expected biologics attachment recovery.

Alphatec (ATEC) delivered earnings and revenue surprises of -22.22% and +1.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alphatec (NASDAQ:ATEC) reported second-quarter 2026 revenue of $214 million, up 15% from a year earlier, as growth in surgical procedures and surgeon adoption supported higher profitability and positive free cash flow. Chairman and CEO Pat Miles said surgical revenue rose 17% to $196 million, while

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Motley Fool Press Release.

Alphatec Holdings (ATEC) has an average rating of buy and mean price target of $15.92, according to